Charles River LaboratoriesCRL
NYSE · USA · Segment 4 of 8 in the Medicine, pharma & life science value chain: CDMO & pharma manufacturing
Preclinical work that drug and biotech companies choose not to do in-house: research models, safety testing, laboratory services through development, and support for cell and gene therapy.
CDMO & pharma manufacturing: Contract development and manufacturing of medicines, the industrial backbone behind the drugs.
Key metrics
Market cap
$13.6B
Price
$298.58
Today
+1.1%
Return YTD
+48.0%
Return 1Y
+91.0%
P/E
—
P/S
3.4
P/B
4.8
Data as of 2026-08-25 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Preclinical models
- Safety testing
- Cell & gene therapy services
Competitors
- ICON
- IQVIA
- Labcorp
Risks
- Biotech funding cycles
- Regulatory changes (animal models)
Supply chain
Supplies →
Same segment: CDMO & pharma manufacturing
Compare CRL
See where Charles River Laboratories sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →